Discover the “ingenuity” of IPA with us at SOT!


The Society of Toxicology is coming to the Baltimore Convention Center from March 12–16, and if you know Baltimore, you know there’s a lot to look forward to in addition to great toxicology research (Maryland crabs and Berger cookies, anyone?). QIAGEN will discuss one of its signature products – Ingenuity Pathway Analysis (IPA), a powerful analysis and search tool that uncovers the significance of ‘omics data and identifies new targets or candidate biomarkers within the context of biological systems.

Join QIAGEN scientist Devendra Mistry for a case study exploring IPA’s utilization and contribution in understanding Nrf2’s protective role in the kidney. Here are the details:

Investigating Nrf2’s Protective Role in Kidney through Transcriptomics and Proteomics Data Interpretation using Ingenuity Pathway Analysis (IPA)

Speaker: Dr. Devendra Mistry, Field Application Scientist, Applied Advanced Genomics Americas, QIAGEN, Inc. – Redwood City
Date and time: Tue, Mar 14, 2017, 12 p.m. to 1 p.m. – Join us for lunch!
Room Assignment: 340
IPA identifies Nrf2 as the key upstream regulator accompanying the activation of detoxification-related pathways and biological processes. Comparison analysis of transcriptomics and proteomics datasets shows enrichment of similar pathways and cellular processes, and highlights IPA as a powerful tool for multi-omics Tox analysis.

In addition to the presentation on IPA, we’ll be at our booth, #1812 in Exhibit Hall E, to answer all your questions and show you some of our most recent advances. We’re looking forward to seeing you in Baltimore, MD, March 12–16!

Reserve your seat for the workshop and get a free lunch!

If you have any questions about meeting up with QIAGEN at SOT, just drop them in the comments section below!

Ali Bierly

Ali Bierly, PhD is a Global Market Manager in Translational Sciences at QIAGEN, and has written on a number of scientific topics in the biotech industry as the author of QIAGEN's Reviews Online. She received her PhD from Cornell University in 2009, studying the immune response to a protozoan parasite, Toxoplasma gondii. Ali has a keen interest in the emerging importance of microRNA and other circulating nucleic acids as biomarkers for disease.

Your email address will not be published. Required fields are marked *